VolitionRx’s (VNRX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of VolitionRx (NYSE:VNRX) in a report issued on Thursday,Benzinga reports. D. Boral Capital currently has a $5.00 price objective on the stock.

Other equities analysts also recently issued research reports about the company. StockNews.com initiated coverage on VolitionRx in a research note on Thursday. They set a “sell” rating for the company. Benchmark reaffirmed a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd.

VolitionRx Trading Up 1.0 %

VolitionRx stock opened at $0.55 on Thursday. The firm has a market capitalization of $50.97 million, a price-to-earnings ratio of -1.53 and a beta of 1.09. The firm’s fifty day moving average price is $0.60 and its two-hundred day moving average price is $0.64. VolitionRx has a 1-year low of $0.43 and a 1-year high of $1.02.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its position in shares of VolitionRx by 15.1% during the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after buying an additional 95,900 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of VolitionRx during the fourth quarter valued at approximately $36,000. Northern Trust Corp lifted its holdings in VolitionRx by 32.0% during the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after acquiring an additional 28,579 shares during the period. Lagoda Investment Management L.P. boosted its position in VolitionRx by 24.3% in the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock worth $4,546,000 after purchasing an additional 1,481,000 shares during the last quarter. Finally, Two Sigma Securities LLC bought a new position in VolitionRx in the 4th quarter valued at $29,000. 8.09% of the stock is currently owned by hedge funds and other institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.